
CardioKinetix
Founded Year
2002Stage
Series F | AliveTotal Raised
$118.8MLast Raised
$50M | 9 yrs agoAbout CardioKinetix
CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.
CardioKinetix Patents
CardioKinetix has filed 31 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
9/18/2015 | 8/25/2020 | Cardiovascular physiology, Cardiac anatomy, Cardiology, Heart diseases, Congenital heart defects | Grant |
Application Date | 9/18/2015 |
---|---|
Grant Date | 8/25/2020 |
Title | |
Related Topics | Cardiovascular physiology, Cardiac anatomy, Cardiology, Heart diseases, Congenital heart defects |
Status | Grant |
Latest CardioKinetix News
Jan 27, 2023
Major Players Boston Scientific Corporation, Medtronic, Edwards Lifesciences Corporation, Abbott Laboratories, ST. JUDE MEDICAL, Biomerics, Comed BV, LivaNova PLC, JenaValve Technology Inc., and CardioKinetix. among others Segmentation Analysis Aortic valvular disease is expected to be the fastest-growing segment in 2022. The indication segment is divided into atrial septal defects, aortic valvular disease, pulmonary valvular disease, patent foramen ovale, ventricular septal defects, mitral valvular disease, patent ductus arteriosus, and others. The aortic valvular disease segment is expected to witness the highest growth rate during the forecast period. There is a connection between aortic valvular disease and the aorta, since the aorta carries oxygenated blood from the heart to the body, and when there is aortic valvular disease, the aorta does not fully open. In order to treat it, a structural cardiac device is implanted through minimally invasive surgical techniques. Therefore, the indication section will be dominated by aortic valvular disease. Heart valve devices are expected to be the fastest-growing segment in 2022. The product type segment is divided into heart valve devices, annuloplasty rings, occluders and delivery systems, transcatheter mitral valve repair, and others. The heart valve devices segment is expected to witness the highest growth rate during the forecast period. It is a one-way valve implanted into the heart as a replacement for a heart valve that does not function properly. A mechanical heart valve, a bioprosthetic tissue valve or an engineered tissue valve are three broad categories of artificial heart valves. Replacement is expected to be the fastest-growing segment in 2022. The procedure segment is divided into repair and replacements. The replacement segment is expected to witness the highest growth rate during the forecast period. As a result of the development of superior, flexible, sophisticated, resilient, and highly effective structural cardiac devices, the need for replacement has increased. A successful long-term alternative to repair methods is a replacement, which increases blood flow and makes the patient live a longer life. Regional Analysis The regional analysis provides a detailed perception of the key regions and the countries. Some of the key countries analyzed for the structural heart devices market include the US, Canada, Mexico, Germany, France, the U.K., Italy, Spain, Russia, China, Japan, India, Brazil, Peru, UAE, South Africa, and Saudi Arabia. The North American region witnessed a major share. Structural heart devices have been a major success in North America due to a large pool of patients, favourable reimbursement scenarios, and advanced healthcare infrastructure. Although minimally invasive surgery such as transcatheter aortic valve implantation (TAVI) and mitral valve repair/replacement may reduce utilization rates over the forecast period, increasing penetration may result in lower utilization rates. Country Analysis Germany Germany's structural heart devices market size was valued at USD 0.92 billion in 2022 and is expected to reach USD 2.18 billion by 2030, at a CAGR of 11.4% from 2023 to 2030. In Germany, the market is expanding due to an increase in surgeries, cardiovascular illnesses, and advanced treatment methods. China China’s structural heart devices market size was valued at USD 0.98 billion in 2022 and is expected to reach USD 2.37 billion by 2030, at a CAGR of 11.7% from 2023 to 2030. As awareness of cardiac disease increases, neonatal screening programs improve, and access to healthcare expands in China, the market is expected to expand. India India's structural heart devices market size was valued at USD 0.76 billion in 2022 and is expected to reach USD 1.8 billion by 2030, at a CAGR of 11.6% from 2023 to 2030. Increasing healthcare facility demand, a favourable reimbursement environment, and an increase in structural heart disease awareness drive the market for structural heart devices in the country. Covid-19 Impact Covid-19 had a major impact on almost all industries, such as electronics, semiconductors, manufacturing, automobile, etc. However, several companies operating in the technology sector have seen increased revenue due to significant changes in consumer preferences toward technological services. In addition, the pandemic has led to significant growth in technology across developing and developed countries. Furthermore, the growth of this market is mainly driven owing to the rising demand for flavored beverages among consumers, propelling the growth of the market across the countries. Buy Now Full Report @ https://greyviews.com/checkout/467/single_user_license Contact Us Browse Related Reports: Veterinary Hematology Analyzers Market Size By Product Type (Table Top Analyzers (Fully Automatic Analyzers and Semiautomatic Analyzers) and Point of Care Analyzers (Cartridge-Based Analyzers and Direct Sample Based Analyzers), By Analysis Parameter (2-Part WBC Differential, 3-Part WBC Differential, 5-Part WBC Differential, and Others), By End-User (Research institutes, Veterinary hospitals and clinics, Veterinary diagnostic centers, point-of-care testing, inhouse-testing, and others), Regions, Segmentation, and Projection till 2030 Structural Heart Devices Market Size By Indication (Atrial Septal Defects, Aortic Valvular Disease, Pulmonary Valvular Disease, Patent Foramen Ovale, Ventricular Septal Defects, Mitral Valvular Disease, Patent Ductus Arteriosus, and Others), By Product Type (Heart Valve Devices, Annuloplasty Rings, Occluders and Delivery Systems, Transcatheter Mitral Valve Repair, and Others), By Procedure(Repair and Replacements), Regions, Segmentation, and Projection till 2030 Shoulder Arthroplasty Market Size By Indication (Arthritis, Fracture/Dislocation, Rotator Cuff Tear Arthropathy, Hill Sachs Defect, and Others), By Device (Shoulder Arthroplasty Resurfacing Implants, Shoulder Arthroplasty Trauma Devices, and Shoulder Arthroplasty Platform Systems), By Procedure (Partial Shoulder Arthroplasty, Total Shoulder Arthroplasty, Reverse Shoulder Arthroplasty, and Revision Shoulder Arthroplasty), Regions, Segmentation, and Projection till 2030
CardioKinetix Frequently Asked Questions (FAQ)
When was CardioKinetix founded?
CardioKinetix was founded in 2002.
Where is CardioKinetix's headquarters?
CardioKinetix's headquarters is located at 925 Hamilton Avenue, Menlo Park.
What is CardioKinetix's latest funding round?
CardioKinetix's latest funding round is Series F.
How much did CardioKinetix raise?
CardioKinetix raised a total of $118.8M.
Who are the investors of CardioKinetix?
Investors of CardioKinetix include U.S. Venture Partners, Tekla Capital Management, SV Health Investors, New Leaf Venture Partners, Panorama Capital and 7 more.
Who are CardioKinetix's competitors?
Competitors of CardioKinetix include Ancora Heart, Respicardia, Cayenne Medical, MiCardia, Bio Control Medical and 12 more.
Compare CardioKinetix to Competitors
Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure
CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).
Bio Control Medical offers implantable devices for the treatment of incontinence and congestive heart failure.

JenaValve develops, manufactures, and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease. The company's transapical aortic valve system is CE-marked and currently marketed in Europe and other markets worldwide. The company was founded in 2006 and is based in Irvine, California.

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation, and is proven to resolve and restore normal mitral valve function. It was formerly known as mValve. The company was founded in 2007 and is based in St. Louis Park, Minnesota.

Cardiac Dimensions develops minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. Its initial technology platform, the CARILLON Mitral Contour System has been designed to address functional mitral regurgitation, utilizing a novel percutaneous approach. The company was founded in 2000 and is based in Kirkland, Washington.